The evaluation of simple morphological, histological and immunohistochemical features (tumor type, grade, peritumoral lymphocytes, MLH1 and p53 expression) could help in the pre-screening phase and molecular characterization for identifying POLE EDMs in EC, increasing the likelihood from 7% to 33% that a mutation may be detected (15) (Figure 3, left and middle panels). The gene discussed is TP53; the disease is neoplasm.